Close Menu

NEW YORK – Invitae announced on Sunday preliminary 2019 revenues of around $216 million, representing 45 percent growth over $147.7 million the prior year but falling short of the consensus Wall Street estimate of $219.9 million and short of its own annual revenue projections of $220 million.  

The company said testing volume grew 60 percent year over year to more than 482,000 samples compared to 303,000 samples in 2018. The company had previously projected that it would accession more than 500,000 samples in 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.